Heading into ASCO, we’re sharing our announcement of a new innovative breast cancer trial sponsored by Natera, called SIGNAL-ER 101. The first patients have been enrolled in this prospective, interventional study, which will evaluate Signatera™ MRD-guided de-escalation in early-stage HR /HER2- breast cancer. “Many women with this type and stage of breast cancer are overtreated, which can have a profound impact on their quality of life,” said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection at Natera. “SIGNAL-ER 101 is a key part of our evidence generation roadmap, to support Signatera-guided treatment optimization without compromising the survival benefit from CDK4/6 inhibitors. This approach also allows patients to get the most effective treatment when Signatera shows it is necessary.” SIGNAL-ER 101 is the first in a series of Natera-sponsored SIGNAL trials designed to demonstrate that MRD-negative patients may be able to delay or defer treatment. ow.ly/C8hj50Z5m2a #ASCO26 #CancerResearch #MRDtesting

"92% of #oncologists report that if their patients knew about #MRDtesting as an option, they would be interested in incorporating it into their #cancer management and monitoring plans," reports Yuri Fesko, MD, Senior Vice President and Chief Medical Officer for Quest Diagnostics.

Myeloma experts @jmikhaelmd and @Bethfaiman discuss how proposed cure definitions are already changing myeloma care, including increased MRD testing to monitor depth of remission after treatment ends. #MRD #MRDtesting #AsktheIMF

NEW PODCAST RELEASE (links below) Believe in Progress: An AACR Foundation Podcast The Cancer Test Most Patients Don’t Know Exists. Two Perspectives, One Goal: Making Cancer Testing Trustworthy and Accessible. Join @AACR for a powerful conversation between an architect of liquid biopsy infrastructure and the patient whose life depends on it. This session dives into the science, the emotional reality, and the future of cancer detection. Featured Guests: Lauren C. Leiman: Executive Director of BLOODPAC and former White House Cancer Moonshot leader. Lauren helps build the regulatory frameworks that ensure blood tests are validated and trusted by clinicians. Mary Royal: Breast cancer survivor, marathoner, and patient advocate. Mary shares her journey of using ctDNA personalized testing to monitor for recurrence and how "Mary 2.0" found reassurance through data. YouTube (video): bit.ly/4wjcvtT Apple Podcasts (audio): bit.ly/3QNs4Ke Spotify (audio): bit.ly/48O6hYY #PrecisionOncology #PrecisionMedicine #BreastCancer #BCSM #MRD #ctDNA #MRDTesting

Join us for our Miami #Myeloma MRD Meeting 2026 🇺🇸 🩸 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW to secure your spot 🔗 👉 us06web.zoom.us/webinar/regi… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-opp… Video Journal of Hematology & Hematological Oncology (VJHemOnc)

Where the #MRD community meets: collaboration and innovation at the 13th Miami #Myeloma MRD Meeting 🇺🇸 🩸 Hear from @DrOlaLandgren, MD, PhD 👉 vjhemonc.com/video/uyp53nx9f… 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at @SylvesterCancer, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with the @theMMRF, @IMFmyeloma, and @HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW for the livestream and secure your spot 🔗 👉 us06web.zoom.us/webinar/regi… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-opp…

What are the differences between Molecular circulating tumor DNA (ctDNA) testing and minimal residual disease (MRD) testing? Now presenting Dr. @Joshua_Reuss! #LungCancer #TargetedTherapies #TrueOrFalse #Molecularprofiling #MRDTesting #ctDNATesting

At the recent Precision Medicine World Conference, Minetta Liu, MD, chief medical officer for Natera oncology, participated in two panel discussions about the importance of molecular residual disease testing. The panelists discussed the role of circulating tumor DNA in recurrence monitoring and its potential utilization in therapy and treatment decisions in the future. Learn more about Signatera™ during our upcoming webinars: ow.ly/waBS50YvqH4 #PMWC26 #Natera #ctDNA #MRDtesting

From discovery to decision making: the evolution of #MRD at the 13th Miami #Myeloma MRD Meeting 🇺🇸 🩸 Hear from @DrOlaLandgren, MD, PhD 👉 vjhemonc.com/video/fahsu7wz9… 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at @SylvesterCancer, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with the @theMMRF, @IMFmyeloma, and @HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW for the livestream and secure your spot 🔗 👉 us06web.zoom.us/webinar/regi… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-opp…

Join us for our Miami #Myeloma MRD Meeting 2026 🇺🇸 🩸 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW to secure your spot 🔗 👉 us06web.zoom.us/webinar/regi… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-opp… Video Journal of Hematology & Hematological Oncology (VJHemOnc)

Join us for our Miami #Myeloma MRD Meeting 2026 🇺🇸 🩸 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at @SylvesterCancer, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with the @theMMRF, @IMFmyeloma, and @HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Hear from @DrOlaLandgren, MD, PhD who tells us about the meeting 👉 vjhemonc.com/video/196jzuy7z… Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW for the livestream and secure your spot 🔗 👉 us06web.zoom.us/webinar/regi… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-opp…

Join us for our Miami #Myeloma MRD Meeting 2026 🇺🇸 🩸 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at @SylvesterCancer, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with @theMMRF, @IMFmyeloma, and @HealthTree for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW to secure your spot 🔗 👉 us06web.zoom.us/webinar/regi… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-opp… Video Journal of Hematology & Hematological Oncology (VJHemOnc)

Even after decades in medicine, nothing can prepare you to hear the words, “you have cancer.” When Dr. James Duke, a retired orthopedic surgeon, faced that diagnosis, he turned to what he knew best: science, innovation and teamwork. With support from his care team, he chose to pursue immunotherapy before surgery and added Signatera™ MRD testing to guide his treatment. The result? A less invasive surgery, preserved quality of life and 18 months recurrence-free. His story is a powerful reminder that informed patients can shape their outcomes. See Dr. Duke's full story here: ow.ly/1zCA50XrZo4 #CancerCare #Signatera #MRDtesting #PrecisionMedicine

The Future of Cancer Care is Here, and It's Precisely Tailored to Each Individual Patient - Kashyap Patel (@KashyappatelMd) @karancushman oncodaily.com/voices/kashyap… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #PrecisionMedicine #PersonalizedMedicine #MRDTesting #GeneticTesting @CancerWorldmag

🎥 MRD in a Minute: Signatera™ Genome At #ASCO 2025, @NateraGenetics President Solomon Moshkevich explains how Signatera Genome makes #MRD testing clearer for physicians & builds confidence for patients. 🎬 Hear the insights: youtube.com/watch?v=GcWHv5k2… #Oncology #MRDTesting

Promise of MRD Testing in GI Cancers - @dougflora2 oncodaily.com/opinion/dougla… @MallaMidhun #MRDTesting #GIOncology #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

🎥 From #ASCO25: Our team captured “MRD Testing in a Minute” with @NateraGenetics. 60 sec videos delivering key clinical insights to help providers stay current & support better patient outcomes. Discover more: youtu.be/WbLkBqG6MJc?si=ZrDc… #MRDTesting #Oncology

One in six oncologists in the BESPOKE CRC trial changed treatment plans for #ColorectalCancer based on ctDNA results. See how #MRDtesting is transforming #CRC care: ow.ly/RkS850Wy7sS

Trials GALAXY and BESPOKE CRC confirm that #ctDNA positivity is a strong predictor of recurrence in #ColorectalCancer. See how #MRDtesting is reshaping surveillance strategies for patients. ow.ly/uLWN50Wy5f9

One in six oncologists in the BESPOKE CRC trial changed treatment plans for #ColorectalCancer based on ctDNA results. See how #MRDtesting is transforming #CRC care: ow.ly/RkS850Wy7sS